Citations

Clear

3942 citation(s) found for "To, Van".

T-Cell Homeostatic Imbalance in Placentas From Women With Human Immunodeficiency Virus in the Absence of Vertical Transmission
Ikumi, Nadia M. , Pillay, Komala , Tilburgs, Tamara , Malaba, Thokozile R. , Dzanibe, Sonwabile , Enninga, Elizabeth Ann L. , Chakraborty, Rana , Myer, Landon , Jaspan, Heather B. , Gray, Clive M. , Enninga, Elizabeth Ann L , Gray, Clive M , Lamorde, Mohammed , Khoo, Saye

Mayo Clinic

The Journal of Infectious Diseases | April 5, 2021 | Volume: 224 | Issue: Supplement_6 | Pages: S670-S682

10.1093/infdis/jiab192 | PMID 33880544 Get It

Abstract Background Implementation of universal antiretroviral therapy (ART) has significantly lowered vertical transmission rates but has also increased numbers of human immunodeficiency virus (HIV)–exposed uninfected children, who remain vulnerable to morbid effects. In the current study, we investigated whether T-cell alterations in the placenta contribute to altered immune status in HIV-exposed uninfected. Methods We analyzed T cells from term placenta decidua and villous tissue and paired cord blood from pregnant women living with HIV (PWH) who initiated ART late in pregnancy (n = 21) with pregnant women not living with HIV (PWNH) (n = 9). Results Placentas from PWH showed inverted CD4/CD8 ratios and higher proportions of tissue resident CD8+ T cells in villous tissue relative to control placentas. CD8+ T cells in the fetal capillaries, which were of fetal origin, were positively correlated with maternal plasma viremia before ART initiation, implying that imbalanced T cells persisted throughout pregnancy. In addition, the expanded memory differentiation of CD8+ T cells was confined to the fetal placental compartment and cord blood but was not observed in the maternal decidua. Conclusions T-cell homeostatic imbalance in the blood circulation of PWH is reflected in the placenta. The placenta may be a causal link between HIV-induced maternal immune changes during gestation and altered immunity in newborn infants in the absence of vertical transmission.
The Range of Cardiogenic Shock Survival by Clinical Stage: Data From the Critical Care Cardiology Trials Network Registry
Lawler, Patrick R. , Berg, David D. , Park, Jeong‐Gun , Katz, Jason N. , Baird-Zars, Vivian M., Barsness, Gregory W. , Bohula, Erin A. , Menon, Venu , Metkus, Thomas S. , Nativi-Nicolau, José , Phreaner, Nicholas , Teuteberg, Jeffrey J. , Lawler, Patrick , Bohula, Erin A , Berg, David , Carnicelli, Anthony , Chaudhry, Sunit‐Preet , Jentzer, Jacob C. , Sinha, Shashank S , Diepen, Sean van , Morrow, David A.

Mayo Clinic

Critical Care Medicine | April 4, 2021 | Volume: 49 | Issue: 8 | Pages: 1293-1302

10.1097/ccm.0000000000004948 | PMID 33861557 Get It

OBJECTIVES: Cardiogenic shock presents with variable severity. Categorizing cardiogenic shock into clinical stages may improve risk stratification and patient selection for therapies. We sought to determine whether a structured implementation of the 2019 Society for Cardiovascular Angiography and Interventions clinical cardiogenic shock staging criteria that is ascertainable in clinical registries discriminates mortality in a contemporary population with or at-risk for cardiogenic shock. DESIGN: We developed a pragmatic application of the Society for Cardiovascular Angiography and Interventions cardiogenic shock staging criteria—A (at-risk), B (beginning), C (classic cardiogenic shock), D (deteriorating), or E (extremis)—and examined outcomes by stage. SETTING: The Critical Care Cardiology Trials Network is an investigator-initiated multicenter research collaboration coordinated by the TIMI Study Group (Boston, MA). Consecutive admissions with or at-risk for cardiogenic shock during two annual 2-month collection periods (2017–2019) were analyzed. PATIENTS: Patients with or at-risk for cardiogenic shock. MEASUREMENTS AND MAIN RESULTS: Of 8,240 CICU admissions reviewed, 1,991 (24%) had or were at-risk for cardiogenic shock. Distributions across the five stages were as follows: A: 33%; B: 7%; C: 16%; D: 23%; and E: 21%. Overall in-hospital mortality among patients with established cardiogenic shock was 39%; however, mortality varied from only 15.8% to 32.1% to 62.5% across stages C, D, and E (Cochran-Armitage p trend < 0.0001). The Society for Cardiovascular Angiography and Interventions stages improved mortality prediction beyond the Sequential Organ Failure Assessment and Intra-Aortic Balloon Pumpin Cardiogenic Shock II scores. CONCLUSIONS: Although overall mortality in cardiogenic shock remains high, it varies considerably based on clinical stage, identifying stage C as relatively lower risk. We demonstrate a pragmatic adaptation of the Society for Cardiovascular Angiography and Interventions cardiogenic shock stages that effectively stratifies mortality risk and could be leveraged for future clinical research.
Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients
Dorst, Daan C.H. van , Dobbin, Stephen J.H. , Neves, Karla B , Herrmann, Joerg , Mathijssen, Ron H.J. , Lang, Ninian N. , Lang, Ninian N , Herrmann, Sandra M. , Versmissen, Jorie , Danser, A.H. Jan

Mayo Clinic

Circulation Research | April 1, 2021 | Volume: 128 | Issue: 7 | Pages: 1040-1061

10.1161/circresaha.121.318051 | PMID 33793337 Get It

The development of a wide range of novel antineoplastic therapies has improved the prognosis for patients with a wide range of malignancies, which has increased the number of cancer survivors substantially. Despite the oncological benefit, cancer survivors are exposed to short- and long-term adverse cardiovascular toxicities associated with anticancer therapies. Systemic hypertension, the most common comorbidity among cancer patients, is a major contributor to the increased risk for developing these adverse cardiovascular events. Cancer and hypertension have common risk factors, have overlapping pathophysiological mechanisms and hypertension may also be a risk factor for some tumor types. Many cancer therapies have prohypertensive effects. Although some of the mechanisms by which these antineoplastic agents lead to hypertension have been characterized, further preclinical and clinical studies are required to investigate the exact pathophysiology and the optimal management of hypertension associated with anticancer therapy. In this way, monitoring and management of hypertension before, during, and after cancer treatment can be improved to minimize cardiovascular risks. This is vital to optimize cardiovascular health in patients with cancer and survivors, and to ensure that advances in terms of cancer survivorship do not come at the expense of increased cardiovascular toxicities.
Association of Virtual Surgical Planning With External Incisions in Complex Maxillectomy Reconstruction
Moore, Eric J. , Price, Daniel L., Abel, Kathryn M. Van , Janus, J.R., Moore, Ethan , Martin, Eli, Morris, Johnathan M., Alexander, Amy E. , Janus, Jeffery R, Moore, Ethan T, Van Abel, Kathryn M , Price, Daniel L. , Martin, Eliot J., Morris, Johnathan M.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 1, 2021 | Volume: 147 | Issue: 6 | Pages: 526

10.1001/jamaoto.2021.0251 | PMID 33792635 Get It

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
Fuchs, Charles S. , Shitara, Kohei , Muro, Kei , Vita, Ferdinando De , Landers, Gregory, Yen, Chia‐Jui , Chau, Ian , Elme, Anneli , Lee, Jeeyun , Özgüroğlu, Mustafa , Catenacci, Daniel V.T. , Yoon, Harry H. , Chen, Erluo, Adelberg, David E., Shih, Chie‐Schin , Shah, Sukrut, Bhagia, Pooja , Yen, Chia-Jui , Özgüroğlu, Mustafa , Chao, Joseph , Tabernero, Josep , Cutsem, Eric Van , Bang, Yung‐Jue , Wainberg, Zev A.

Mayo Clinic

JAMA Oncology | April 1, 2021 | Volume: 7 | Issue: 6 | Pages: 895

10.1001/jamaoncol.2021.0275 | PMID 33792646 Get It

Prophylactic Clipping For The Prevention Of Delayed Bleeding After Non-Pedunculated Colorectal Polyp Resection: An Individual Patient Data Meta-Analysis
Turan, Ayla , Pohl, Heiko , Matsumoto, M, Lee, Benjamin B , Aizawa, Masato, Desideri, F. , Raju, Gottumukkala S. , Luba, Daniel G., Gurudu, S, Ramirez, Francisco C. , Lin, W-R, Atsma, Femke , Rex, DK, Lim, Brian S. , Togashi, Kazutomo , Umar, Sarah B. , Cw, Chen, Droste, Jochiim Terhaar Sive, Kemper, Gijs , Siersema, Peter D. , Geenen, Erwin van, Matsumoto, M, Lee, B, Albéniz, Eduardo , Barret, Maximilien , Kwok, Karl K. , Coriat, Romain , Schrauwen, Ruud W.M.

Mayo Clinic

Endoscopy | March 31, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1724468 Get It

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, Pataje G.S. , Citrin, Deborah E. , Hildesheim, Jeffrey, Ahmed, Mansoor M. , Venkatachalam, Sundar, Riscuta, Gabriela , Xi, Dan , Zheng, Guangrong , Deursen, Jan van, Goronzy, Jörg J. , Kron, Stephen J. , Campisi, Judith , Brown, Stephen L. , Niedernhofer, Laura J. , Gius, David , Schmitt, Clemens A. , Abazeed, Mohamed E. , Kirkland, James L. , Lowe, Scott W. , Mendonca, Marc S. , Burma, Sandeep , Zhou, Daohong , Coleman, C. Norman , Prasanna, Pataje G , Goronzy, Jorg , Sharpless, Norman E , Campisi, Judith , Georgakilas, Alexandros G , Paris, Francois , Gewirtz, David A , Schmitt, Clemens A , Abazeed, Mohamed E , Kirkland, James L , Richmond, Ann , Romesser, Paul B , Gil, Jesus , Mendonca, Marc S , Niedernhofer, Laura J , Anscher, Mitchell S. , O’Loghlen, Ana , Georgakilas, Alexandros G. , Romesser, Paul B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 31, 2021 | Volume: 113 | Issue: 10 | Pages: 1285-1298

10.1093/jnci/djab064 | PMID 33792717 Get It

Abstract Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.
Short and long‐term outcomes of three‐dimensional printed surgical guides and virtual surgical planning versus conventional methods for fibula free flap reconstruction of the mandible: Decreased nonunion a
May, Matthew M. , Howe, Benjamin M., O’Byrne, Thomas J., Alexander, Amy E. , Morris, Jonathon M., Moore, Eric J. , Kasperbauer, Jan L. , Janus, Jeffrey R. , Abel, Kathryn M. Van , Dickens, Hunter J., Van Abel, Kathryn M , Howe, Benjamin M. , Price, Daniel L.

Mayo Clinic

Head & Neck | March 31, 2021 | Volume: 43 | Issue: 8 | Pages: 2342-2352

10.1002/hed.26688 | PMID 33786910 Get It

Abstract Background To determine whether virtual surgical planning and three‐dimensional printed cutting guides (3D/VSP) improved radiographic bone union compared to conventional methods (CM) in fibula free flap (FFF) reconstruction of the mandibles. Methods Retrospective study from the years 2000–2018 at a tertiary hospital. Osseous union was evaluated by a radiologist blinded to each patient's treatment. Results Two hundred sixty patients who underwent FFF tissue transfer, 28 with VSP and 3D cutting guides. Bony union was not achieved in 46 (20%) patients who underwent CM compared to 1 (4%) of patients with VSP and guides ( p = 0.036). FFF complication was significantly higher in CM with 87 patients (38%) compared to three patients (11%) in 3D/VSP ( p = 0.005). Median time to bony union for patients who underwent CM was 1.4 years compared to 0.8 years in 3D/VSP. Conclusions 3D/VSP reduced the rate of radiographic nonunion and flap‐related complications in FFF reconstruction for mandibular defects.
Regenerative Readiness: Innovation Meets Sociology
Webster, Andrew , Terzic, André , Terzic, Andre

Mayo Clinic

Regenerative Medicine | March 30, 2021 | Volume: 16 | Issue: 3 | Pages: 189-195

10.2217/rme-2021-0034 | PMID 33781086 Get It